drugset / Trial / NCT02306733

Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally

NCT02306733

Phase 3 Unknown 200 enrolled Cairo University
RandomizedParallel-groupDouble-blindTreatment

Summary

200 women with PPH will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) and group 2 will receive oxytocin 10 IU (Syntocinon®, Novartis, Switzerland). The investigators will not include a control group for ethical reasons.

Timeline

Start
2014-11
Primary completion
2017-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxytocin Peptide 10 iu Intravenous
Comparator ergometrine Unknown 400 ug Intravenous

Indications

No indication recorded.